Daiichi Sankyo to acquire Plexxikon for $805 million

Daiichi Sankyo Co Ltd has reached an agreement to acquire Plexxikon Inc of the US, which has a product for metastatic melanoma in Phase 3, along with a companion diagnostic. The Japanese company is offering $805 million for Plexxikon.